Every 424B that UNITED HEALTH PRODUTS INC (UEEC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow UEEC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UEEC filings page.
United Health Products, Inc. is updating its S-1 resale registration to incorporate its June 30, 2026 quarterly report, covering up to 25,669,288 shares of common stock for resale by a selling security holder. The company reported no revenue and a six-month net loss of $599,982, improving from a $1,854,316 loss a year earlier. Cash was $24,495 with total assets of $247,985 and a stockholders’ deficit of $4,442,816, and management states there is substantial doubt about its ability to continue as a going concern.
Current liabilities of $4,188,234 and a working capital deficit of $4,123,570 are funded mainly through convertible notes, related-party debt, and equity facilities, including an Any Market Purchase Agreement with Alumni Capital for up to $4,000,000 of stock purchases. The company continues to pursue FDA Class III Premarket Approval for its CelluSTAT hemostatic gauze and is working with NAMSA as proposed Sponsor for a new IDE clinical study while addressing an FDA Warning Letter and related CAPA and GCP audit requirements. Disclosure controls and procedures were assessed as not effective, and common shares outstanding were 262,685,588 as of August 14, 2026.
United Health Products, Inc. files a prospectus supplement to register 25,669,288 shares of common stock for resale by a selling security holder under its effective Form S-1. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026.
The supplement notes the Company’s OTCQB last quoted price of $0.054 per share as of May 21, 2026, and states shares issued and outstanding were 260,385,588 as of May 15, 2026. The 10-Q discloses a going concern warning, negative working capital, deferred offering costs of $169,582, and derivative liabilities of $118,844 as of March 31, 2026.
United Health Products, Inc. registers 25,669,288 shares of common stock for resale by Alumni Capital LP pursuant to agreements the company entered into on December 16, 2025. The registered shares comprise (i) 15,000,000 shares issuable under an Any Market Purchase Agreement (AMPA), (ii) 3,484,321 shares issuable upon exercise of a five‑year Commitment Warrant at $0.07462 per share, and (iii) 7,184,967 shares issuable upon conversion of a senior convertible note with an initial conversion price of $0.06039 per share. Alumni may sell the shares on the OTCQB (ticker UEEC) or otherwise; the company will not receive proceeds from Alumni’s resale activity, although it may receive proceeds if it elects to sell shares to Alumni under the AMPA or if the Commitment Warrant is exercised for cash. The prospectus discloses that the company had 258,690,253 shares outstanding prior to this offering and presents an assumed post‑issuance figure of 284,359,541 shares if all referenced issuances occur.